DSIP insomnia-study findings
DSIP Pen is listed with 5mg / 10mg variants. In a 1992 double-blind study of 16 patients with chronic insomnia, significant objective effects were judged weak and potentially partly due to an incidental placebo-group change. Subjective sleep quality did not improve. DSIP insomnia study.
That combination of findings is narrower than a general sleep-benefit claim. The study provides a specific small-trial result, not validation of the pen listed here. DSIP insomnia study.
Objective and subjective sleep outcomes
The trial used polysomnography and subjective ratings separately. A statement about an objective sleep measure is therefore not automatically a statement about how patients rated their sleep. DSIP insomnia study.
DSIP, emideltide and safety concerns
FDA's safety table uses Emideltide (DSIP), and its July 2026 briefing identifies a nine-amino-acid sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. These source records explain the research name. They do not verify the formulation of this pre-filled DSIP pen. FDA compounding safety communication, FDA emideltide assessment.
The pen is listed with 5mg / 10mg variants. That notation is not a concentration or an administration amount. FDA's separate concerns about immune responses and peptide characterization concern compounded emideltide, rather than a finding that the catalogue amount establishes safety. FDA compounding safety communication.
The DSIP vial also lists 5mg / 10mg variants. These are presentation amounts, without establishing equivalence to the pen or to the material in the insomnia study. DSIP insomnia study.
